PE20151940A1 - Derivados de triazina - Google Patents

Derivados de triazina

Info

Publication number
PE20151940A1
PE20151940A1 PE2015002303A PE2015002303A PE20151940A1 PE 20151940 A1 PE20151940 A1 PE 20151940A1 PE 2015002303 A PE2015002303 A PE 2015002303A PE 2015002303 A PE2015002303 A PE 2015002303A PE 20151940 A1 PE20151940 A1 PE 20151940A1
Authority
PE
Peru
Prior art keywords
triazine
triazine derivatives
imidazo
cyclopropyl
tetrahydrofuran
Prior art date
Application number
PE2015002303A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Allen Chappie
Christopher John Helal
Patrick Robert Verhoest
Jamison Bryce Tuttle
Bethany Lyn Kormos
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20151940A1 publication Critical patent/PE20151940A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2015002303A 2013-05-02 2014-04-23 Derivados de triazina PE20151940A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361818650P 2013-05-02 2013-05-02

Publications (1)

Publication Number Publication Date
PE20151940A1 true PE20151940A1 (es) 2016-01-21

Family

ID=50841902

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002303A PE20151940A1 (es) 2013-05-02 2014-04-23 Derivados de triazina

Country Status (33)

Country Link
US (3) US8933224B2 (enExample)
EP (1) EP2991989B1 (enExample)
JP (1) JP6263606B2 (enExample)
KR (1) KR101770905B1 (enExample)
CN (1) CN105164134B (enExample)
AP (1) AP2015008843A0 (enExample)
AR (1) AR096161A1 (enExample)
AU (1) AU2014261070A1 (enExample)
BR (1) BR112015027760A8 (enExample)
CA (1) CA2910759C (enExample)
CL (1) CL2015003037A1 (enExample)
CR (1) CR20150591A (enExample)
CU (1) CU20150144A7 (enExample)
DK (1) DK2991989T3 (enExample)
DO (1) DOP2015000271A (enExample)
EA (1) EA027936B1 (enExample)
EC (1) ECSP15050110A (enExample)
ES (1) ES2637816T3 (enExample)
GE (1) GEP201706675B (enExample)
MA (1) MA38559B1 (enExample)
MD (1) MD20150103A2 (enExample)
MX (1) MX2015015163A (enExample)
NI (1) NI201500157A (enExample)
NZ (1) NZ712949A (enExample)
PE (1) PE20151940A1 (enExample)
PH (1) PH12015502462A1 (enExample)
SG (1) SG11201508201VA (enExample)
TN (1) TN2015000490A1 (enExample)
TW (1) TWI508966B (enExample)
UA (1) UA111696C2 (enExample)
UY (1) UY35547A (enExample)
WO (1) WO2014177977A1 (enExample)
ZA (1) ZA201508968B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027936B1 (ru) * 2013-05-02 2017-09-29 Пфайзер Инк. Производные имидазотриазина в качестве ингибиторов фосфодиэстеразы 10 (pde10)
AU2017323584C1 (en) 2016-09-09 2020-09-17 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
EP3801499B1 (en) 2018-06-07 2024-02-28 Disarm Therapeutics, Inc. Inhibitors of sarm1
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
EP4049662A4 (en) * 2019-10-21 2023-11-01 SK Biopharmaceuticals Co., Ltd. USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUNDS TO PREVENT, RELIEF OR TREAT COGNITIVE DISORDERS OR TO IMPROVE COGNITIVE FUNCTION
TW202339750A (zh) * 2022-02-02 2023-10-16 比利時魯汶大學 用於抑制yap/taz-tead之四氫吡啶并嘧啶及相關類似物
CN117486878A (zh) * 2023-10-27 2024-02-02 扬州市普林斯医药科技有限公司 一种恩那司他的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US20070167426A1 (en) 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
TW200716102A (en) 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
US8207370B2 (en) 2006-09-26 2012-06-26 Kaneka Corporation Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
DE102007059723A1 (de) 2007-12-12 2009-06-18 Siemens Medical Instruments Pte. Ltd. Hörvorrichtung mit Batterieklappenmodul
PE20091057A1 (es) 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
JP5641664B2 (ja) 2009-10-30 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap イミダゾ[1,2−b]ピリダジン誘導体およびPDE10阻害剤としてのそれらの使用
ES2627703T3 (es) 2010-01-22 2017-07-31 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Inhibidores de PI3·quinasa
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
AR081428A1 (es) 2010-05-28 2012-08-29 Biocryst Pharm Inc Derivados heterociclicos condensados nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para suprimir una respuesta inmune o tratar cancer.
US20130085161A1 (en) 2010-06-17 2013-04-04 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
BR112013021366A2 (pt) * 2011-02-23 2016-09-13 Pfizer imidazo[5,1-f][1,2,4]triazinas para o tratamento de desordens neurológicas
EA027936B1 (ru) * 2013-05-02 2017-09-29 Пфайзер Инк. Производные имидазотриазина в качестве ингибиторов фосфодиэстеразы 10 (pde10)

Also Published As

Publication number Publication date
UA111696C2 (uk) 2016-05-25
ECSP15050110A (es) 2017-08-31
JP6263606B2 (ja) 2018-01-17
ZA201508968B (en) 2017-11-29
KR20160003234A (ko) 2016-01-08
TW201506027A (zh) 2015-02-16
MA38559B1 (fr) 2018-04-30
CA2910759C (en) 2018-01-16
CN105164134B (zh) 2017-09-22
TWI508966B (zh) 2015-11-21
KR101770905B1 (ko) 2017-08-23
EP2991989B1 (en) 2017-06-28
TN2015000490A1 (fr) 2017-04-06
US9145427B2 (en) 2015-09-29
WO2014177977A1 (en) 2014-11-06
MX2015015163A (es) 2016-02-22
EP2991989A1 (en) 2016-03-09
GEP201706675B (en) 2017-05-25
EA027936B1 (ru) 2017-09-29
JP2016517877A (ja) 2016-06-20
BR112015027760A8 (pt) 2018-05-08
US9296761B2 (en) 2016-03-29
CN105164134A (zh) 2015-12-16
US20150080401A1 (en) 2015-03-19
UY35547A (es) 2014-11-28
NI201500157A (es) 2015-11-30
AR096161A1 (es) 2015-12-09
EA201591819A1 (ru) 2016-05-31
DOP2015000271A (es) 2016-02-29
MD20150103A2 (ro) 2016-02-29
CA2910759A1 (en) 2014-11-06
HK1213885A1 (zh) 2016-07-15
CU20150144A7 (es) 2016-04-25
NZ712949A (en) 2017-04-28
US20140329820A1 (en) 2014-11-06
US8933224B2 (en) 2015-01-13
AP2015008843A0 (en) 2015-11-30
CL2015003037A1 (es) 2016-04-22
PH12015502462A1 (en) 2016-02-22
ES2637816T3 (es) 2017-10-17
CR20150591A (es) 2016-01-04
AU2014261070A1 (en) 2015-10-29
US20150353579A1 (en) 2015-12-10
DK2991989T3 (en) 2017-07-31
SG11201508201VA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
PE20151940A1 (es) Derivados de triazina
CR20130280A (es) Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
PE20170403A1 (es) COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER
GT201400213A (es) Inhibidores de diacilglicerol aciltransferasa 2
PE20170144A1 (es) 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet
UY39887A (es) (r)-(2-cloro-3-(trifluorometil)fenil)(1-(5-fluoropirimidin2-il)-4-metil-6,7-dihidro-1h-[1,2,3]triazolo-[4,5-c]piridin5(4h)-il)metanona como modulador del receptor p2x7
PE20152033A1 (es) Heterociclos bicicliclos como inhibidores de fgfr
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
MX2015003538A (es) Derivados de 3-fenilisoxazolina con accion herbicida.
UY35935A (es) Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
BR112014032338A2 (pt) cristais de sal
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
CR20140091A (es) Nuevos derivados dihidroquinolina-2-ona
PE20151605A1 (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y analogos de los mismos como inhibidores de autotaxina
PE20160026A1 (es) Compuestos heterociclicos como agentes para control de plagas
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
BR112015032132A2 (pt) cristais de base livre
UY33888A (es) Derivados de (1,2,4) triazolo [4,3-a) quinoxalina como inhibidores de fosfodiesterasas
PE20160593A1 (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CR20140222A (es) Nuevos derivados de [1,2,3] triazolo [4,5-d] pirimidina como agonistas del receptor 2 de agonistas canabinoides
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
PE20171104A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
PE20160125A1 (es) Pirazolpiridinas sustituidas
PE20160902A1 (es) Inhibidores tetraciclicos de autotaxina

Legal Events

Date Code Title Description
FD Application declared void or lapsed